Treatment of helicobacter pylori infection

Helicobacter

Volumn 14, Issue SUPPL. 1, 2009, Pages 46-51

  O'Connor, Anthony ^b   Gisbert, Javier ^a   O'Morain, Colm ^b  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Compliance; Helicobacter; Rescue therapy; Second line therapy; Sequential therapy; Susceptibility testing; Triple therapy

Indexed keywords

AMOXICILLIN; BACTERIAL VACCINE; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; LEVOFLOXACIN; METRONIDAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; BONE MARROW TOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; ERADICATION THERAPY; EUROPE; EYE DISEASE; FECES; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LIVER TOXICITY; NORTH AMERICA; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEQUENTIAL ANALYSIS; SIDE EFFECT; TENDINITIS; TREATMENT DURATION; VACCINATION;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 69449087733     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2009.00704.x     Document Type: Review

References (63)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 56 : 772 781. (Pubitemid 46854190)
2. Vakil NH. pylori treatment: new wine in old bottles? Am J Gastroenterol 2009 104 : 26 30.
3. Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996 1 : 138 44G.
4. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 1825.
5. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States. Dig Dis Sci 2000 45 : 265 271.
6. Saad RJ, Chey WD. Treatment of Helicobacter pylori infection in 2006. Gastroenterol Hepatol Annu Rev 2006 1 : 30 5.
7. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006 28 : 1960 1966.
8. Mégraud FH. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004 53 : 1374 1384.
9. Romano M, Iovene MR, Russo MI, Rocco A, Salerno R, Cozzolino D, Pilloni AP, Tufano MA, Vaira D, Nardone G. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008 61 : 1112 1115.
10. Boyanova L Prevlance of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009 58 (Pt 7 930 935.
11. De Francesco V, Margiotta M, Zullo A, Hassan C, Giorgio F, Burattini O, et al. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy. J Antimicrob Chemother 2007 59 : 783 785. (Pubitemid 47073419)
12. Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007 12 : E3 4.
13. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001 161 : 1217.
14. Calvet X, García N, López T, Gisbert JP, Gené E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 603 609. (Pubitemid 30240753)
15. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrin Ni, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Int Med 2007 147 : 553 562.
16. Gisbert JP. Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008 21 : 14.
17. Gisbert JP, Javares JM. Review article: Helicobacter pylori" rescue" regimen when proton pump inhibitor based-triple therapies fail. Aliment Pharmacol Ther 2002 16 : 1047 1057.
18. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001 36 : 690 700.
19. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, Realdi G. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002 97 : 857 860.
20. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008 14 : 7361 7370.
21. Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, et al. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008 103 : 71 6.
22. Miyachi H, Miki I, Aoyama N, Shirasaka D, Matsumoto Y, Toyoda M, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006 11 : 243 249.
23. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium. Helicobacter 2006 11 : 441 445.
24. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007 51 : 346 349.
25. Tankovic J, Lascols C, Sculo Q, Petit JC, Soussy CJ. Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 2003 47 : 3942 3944.
26. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, et al. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007 29 : 389 396.
27. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 2009 14 : 61 5.
28. Chang WL, Sheu BS, Cheng HC, Yang YJ, Yang HB, Wu JJ Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan. J Gastroenterol Hepatol 2009 May 20. Epub ahead of print.
29. van der Linden PD, Sturkenboom MC, Herings RM, Leufkens HG, Stricker BH. Fluoroquinolones and risk of Achilles tendon disorders. BMJ 2002 324 : 1306 1307.
30. Spahr L, Rubbia-Brandt L, Marinescu O, Armenian B, Hadengue A. Acute fatal hepatitis related to levofloxacin. J Hepatol 2001 35 : 308 309.
31. Gisbert JP, Pajares JM. Helicobacter pylori"rescue" therapy after failure of two eradication treatments. Helicobacter 2005 10 : 363 372.
32. Suzuki S, Suzuki H, Nishizawa T, Kaneko F, Ootani S, Muraoka H, Saito Y, Kobayashi I, Hibi T. Past rifampicin dosing determines rifabutin resistance of Helicobacter pylori. Digestion 2009 79 : 1 4.
33. De Francesco V, Ierardi E, Hassan C, Zullo A. Furazolidone therapy for Helicobacter pylori: is it effective and safe? World J Gastroenterol 2009 21 : 15.
34. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007 26 : 1537 1542.
35. Gisbert JP, Calvet X, Bujanda L, Marcos S, Gisbert JL, Pajares JM. 'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 2003 8 : 90 94. (Pubitemid 36522911)
36. Gonzalez Carro P, Perez Roldan F, De Pedro Esteban A, Legaz Huidobro ML, Soto Fernandez S, Roncero Garcia Escribano O, Esteban Lopez-Jamar JM, Pedraza Martin C, Ruiz Carrillo F. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol 2007 22 : 60 63.
37. Apseloff G. Severe neutropenia among healthy volunteers given rifabutin in clinical trials. Clin Pharmacol Ther 2003 74 : 591 592.
38. Bhagat N, Read RW, Rao NA, et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virusnegative immunocompetent individuals. Ophthalmology 2001 108 : 750 752.
39. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009 15 : 860 864.
40. Abbas Z, Yakoob J, Abid S, Jafri W, Islam M, Azam Z, Hilal I. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig Dis Sci 2008 Dec 5. [Epub ahead of print].
41. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005 21 : 91 6.
42. Buzas GM, Jozan J. Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. J Gastroenterol Hepatol 2007 22 : 1571 1581.
43. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998 115 : 1272 1277.
44. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003 17 : 1333 1343.
45. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009 7 : 145 148.
46. Vakil N, Vaira D. Sequential therapy for Helicobacter pylori: time to consider making the switch? JAMA 2008 17 : 300.
47. Tong JL, Ran ZH, Shen J, Xiao SD. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009 34 : 41 53.
48. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008 148 : 923 931.
49. Caselli M, Zullo A, Maconi G, Parente F, Alvisi V, Casetti T, et al. "Cervia II Working Group Report 2006″: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy. Dig Liver Dis 2007 39 : 782 789.
50. O'Morain CA, O'Connor JP. Is sequential therapy superior to standard triple therapy for the treatment of Helicobacter pylori infection? Nat Clin Pract Gastroenterol Hepatol 2009 6 : 8 9.
51. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009 14 : 109 118.
52. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998 115 : 1278 1282. (Pubitemid 28485621)
53. Axon AT. Treatment of Helicobacter pylori: an overview. Aliment Pharmacol Ther 2000 14 (Suppl. 3 1 6.
54. Scaccianoce G, Zullo A, Hassan C, Gentili F, Cristofari F, Cardinale V, Gigliotti F, Piglionica D, Morini S. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 2008 12 : 251 256.
55. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008 13 : 261 268.
56. Cremonini F, Di Caro S, Covino M, Armuzzi A, Gabrielli M, Santarelli L, Nista EC, Cammarota G, Gasbarrini G, Gasbarrini A. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002 97 : 2744 2749.
57. Graham DY, Opekun AR, Osato MS, El-Zimaity HM, Lee CK, Yamaoka Y, Qureshi WA, Cadoz M, Monath TP. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004 53 : 1235 1243.
58. Malfertheiner P, Schultze V, Rosenkranz B, et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I study. Gastroenterology 2008 135 : 787 795.
59. Seppälä K, Kosunen TU, Veijola L, Sipponen P, Arkkila PE, Rautelin H, Tilvis R. Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects. Scand J Gastroenterol 2008 43 : 1149 1150.
60. Rokkas T, Sechopoulos P, Robotis I, Margantis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009 104 : 21 5.
61. Gisbert JP, Gisbert JL, Marcos S, Jimenez-Alonso I, Moreno-Otero R, Pajares JM. Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment Pharmacol Ther 2008 27 : 346 354.
62. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002 53 : 163 171.
63. Stenström B, Mendis A, Marshall B. Helicobacter pylori- the latest in diagnosis and treatment. Aust Fam Physician 2008 37 : 608 612.